Q-omics provides the consensus-scored KBTBD12 profile across patient tissues and cancer cell-line models. KBTBD12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KBTBD12 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KBTBD12 RNA expression shows 14,636 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UVM, KIRC, and SARC as cancer lineages where KBTBD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD12 survival associations across molecular data types. KBTBD12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD12 RNA expression–survival associations across cancer types. High KBTBD12 expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRP, UCEC, LUAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KBTBD12 RNA expression.
This table summarizes KBTBD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KBTBD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD12 shows lower tumor expression in KIRC, KIRP, COAD, HNSC and BRCA and higher tumor expression in LUAD. The KIRC box plot shows higher KBTBD12 RNA expression in normal versus tumor tissue (log2 FC = −1.010, t-test p < 0.001).
This table shows molecular features associated with KBTBD12 in patient tissues and cancer cell lines. In patient samples, KBTBD12 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
